Treatment of acute myeloid leukemia

被引：42

作者：

Estey, Elihu H. ^{[1
]}

机构：

[1] Seattle Canc Care Alliance, Seattle, WA USA

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷 / 01期

关键词：

RISK MYELODYSPLASTIC SYNDROME; ACUTE MYELOGENOUS LEUKEMIA; STEM-CELL TRANSPLANTATION; TRANS-RETINOIC ACID; CORE-BINDING-FACTOR; COMPLEX KARYOTYPE; ELDERLY-PATIENTS; DOSE CYTARABINE; CLINICAL-TRIALS; AML;

D O I：

10.3324/haematol.2008.001263

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：10 / 16

页数：7

共 33 条

[1]

Bloomfield CD, 1998, CANCER RES, V58, P4173

[2] Treatment of Core-Binding-Factor in Acute Myelogenous Leukemia With Fludarabine, Cytarabine, and Granulocyte Colony-stimulating Factor Results in Improved Event-free Survival [J].

Borthakur, Gautam ;

Kantarjian, Hagop ;

Wang, Xuemei ;

Plunkett, William K., Jr. ;

Gandhi, Varsha V. ;

Faderl, Stefan ;

Garcia-Manero, Guillermo ;

Ravandi, Farhad ;

Pierce, Sherry ;

Estey, Elihu H. .

CANCER, 2008, 113 (11) :3181-3185

[3] Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype [J].

Breems, Dimitri A. ;

Van Putten, Wim L. J. ;

De Greef, Georgine E. ;

Van Zelderen-Bhola, Shama L. ;

Gerssen-Schoorl, Klasien B. J. ;

Mellink, Clemens H. M. ;

Nieuwint, Aggie ;

Jotterand, Martine ;

Hagemeijer, Anne ;

Beverloo, H. Berna ;

Lowenberg, Bob .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4791-4797

[4]

BURNETT AK, 2006, BLOOD, V108

[5] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment [J].

Burnett, Alan K. ;

Milligan, Donald ;

Prentice, Archie G. ;

Goldstone, Anthony H. ;

McMullin, Mary F. ;

Hills, Robert K. ;

Wheatley, Keith .

CANCER, 2007, 109 (06) :1114-1124

[6] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[7] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? [J].

Cornelissen, Jan J. ;

van Putten, Wim L. J. ;

Verdonck, Leo F. ;

Theobald, Matthias ;

Jacky, Emanuel ;

Daenen, Simon M. G. ;

Kooy, Marinus van Marwijk ;

Wijermans, Pierre ;

Schouten, Harry ;

Huijgens, Peter C. ;

van der Lelie, Hans ;

Fey, Martin ;

Ferrant, Augustin ;

Maertens, Johan ;

Gratwohl, Alois ;

Lowenberg, Bob .

BLOOD, 2007, 109 (09) :3658-3666

[8] Implications of potential cure in acute myelogenous leukemia: Development of subsequent cancer and return to work [J].

deLima, M ;

Strom, SS ;

Keating, M ;

Kantarjian, H ;

Pierce, S ;

OBrien, S ;

Freireich, E ;

Estey, E .

BLOOD, 1997, 90 (12) :4719-4724

[9]

ESTEY E, 2007, BLOOD, V110

[10]

ESTEY E, 2003, LEUKEMIA, V198, P257

← 1 2 3 4 →